A Norway-based coalition that partners between public, private, philanthropic, and civil organizations is currently investing in new platform technologies for rapid vaccine research and development and other interventions for pandemics and endemics. The organization is currently investing from their current 5-year plan. The organization is stage agnostic with typical check size being flexible but ranging from $1-100M USD. The organization is open to any geographic regions but is looking to invest in the global south in particular. Investments are typically made through non-dilutive funding but can explore other funding opportunities including equity.
The organization invests in the infectious disease space whether that be vaccines, MABs, or other pandemic-preventing interventions; generally speaking, biotech companies in pandemic-related indications. It is unlikely that the organization would look at diagnostics, devices or digital health unless there was a very specific pandemic-preparedness value proposition. The organization is stage-agnostic and will typically meet with companies from pre-clinical stages to Phase II.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment